Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Free Cash Flow (2016 - 2020)

Alterity Therapeutics has reported Free Cash Flow over the past 3 years, most recently at -$5.2 million for Q4 2018.

  • For Q4 2018, Free Cash Flow fell 475.87% year-over-year to -$5.2 million; the TTM value through Jun 2019 reached -$6.1 million, down 5.57%, while the annual FY2025 figure was -$7.4 million, 10.27% up from the prior year.
  • Free Cash Flow for Q4 2018 was -$5.2 million at Alterity Therapeutics, down from -$47278.4 in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$47278.4 in Q2 2018 and troughed at -$5.5 million in Q2 2016.
  • A 3-year average of -$2.8 million and a median of -$2.7 million in 2017 define the central range for Free Cash Flow.
  • On a YoY basis, Free Cash Flow climbed as much as 98.93% in 2018 and fell as far as 475.87% in 2018.
  • Year by year, Free Cash Flow stood at -$449190.3 in 2016, then tumbled by 100.19% to -$899256.0 in 2017, then crashed by 475.87% to -$5.2 million in 2018.
  • Business Quant data shows Free Cash Flow for ATHE at -$5.2 million in Q4 2018, -$47278.4 in Q2 2018, and -$899256.0 in Q4 2017.